Document is current

Article History

Received: 23 September 2022

Accepted: 15 June 2023

First Online: 25 June 2023

Declarations

:

: The authors declare that they have no conflict of interest. AL has received personal compensation for consulting, serving on a scientific advisory board, speaking or other activities from Alexion, Bristol Myers Squib, Janssen, Biogen, Merck Serono, Novartis, Sanofi/Genzyme. Her institutions have received research grants from Novartis.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Patients gave written informed consent to being included in the original projects. Additional consent was not required for this secondary analysis, for which patients’ privacy and anonymity was guaranteed.

: Not applicable.

: Additional file: Appendix. Source of data of calibration sample. Supplementary Table 1. Item residual correlations and items which were removed. Supplementary Table 2. MSQOL-54 item parameter estimates and misfit. Supplementary Fig. 1. Comparative performance in terms of gain/loss of each measure for each simulation, in comparison to the simulation where all items were administered. Supplementary Table 3. MCAT summary performance measures (mean, min-max) on group factors for each simulation. Supplementary Fig. 2. Relationship between number of items administered and level of health-related quality of life in other simulations performed in the study.